Gut Microbiota Metabolic Reprogramming Drives Endocrine and Immune Resistance in Hormone-Dependent Cancers
Cancers · 12.04.2026 · 18 (8) · 1218
DOI: 10.3390/cancers18081218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.04.2026. Verfasst von Zhengqin Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310022, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform, National Natural Science Foundation of China.
Abstract (Originalsprache)
The gut microbiota, acting as a critical extrinsic endocrine organ, is profoundly involved in the pathological evolution and therapeutic response of hormone-dependent malignancies. This review elucidates the core mechanisms governing the microbiota, endocrine, and immune triple-axis. Multi-omic and biochemical evidence demonstrates that microbial metabolic networks, comprising the estrobolome, androbolome, and progestobolome/corticobolome, rely on enzymatic systems such as β-glucuronidases (GUS) and steroid-17,20-desmolases to execute hormone deconjugation and structural modification, thereby modulating systemic steroid exposure. Concurrently, microbe-derived metabolites, such as secondary bile acids and purine derivatives, act as inter-kingdom messengers. These metabolites remodel the tumor immune microenvironment by antagonizing hormone receptors and activating specific signaling axes, such as the Inosine-A2AR pathway. By modulating localized immune cells like effector T cells and myeloid cells, they play a pivotal role in tumor immune evasion. Furthermore, pharmacomicrobiomics reveals a bidirectional regulation between anti-tumor agents and the gut microbiota, where endocrine and immunotherapeutic drugs can induce microbial dysbiosis, while specific gut taxa contribute to primary or acquired resistance by enzymatically inactivating drugs (e.g., reductive inactivation of Enzalutamide) or providing hormonal precursors through bypass pathways. Facing translational challenges, such as real-world microbiome complexity and the colonization resistance of indigenous flora, we propose treating the human body as a unified host–microbe holobiont system. Future research should leverage gnotobiotic models and genetic causal inference to establish functional causality. These efforts will facilitate the development of precision tools, including ubiquitin–proteasome system (UPS) modulators, microbial enzyme inhibitors, and engineered live biotherapeutics. Collectively, these systems biology strategies offer a robust framework for overcoming therapeutic resistance in hormone-dependent malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310022, China.
- Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou 310022, China.
- Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China.
ORCID-Profile: Liefeng Ma
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation
Zitieren
APA
Zhu, Z., Yang, Y., Pan, L., Ma, L., & Fang, L. (2026). Gut Microbiota Metabolic Reprogramming Drives Endocrine and Immune Resistance in Hormone-Dependent Cancers. Cancers, 18(8), 1218. https://doi.org/10.3390/cancers18081218
Vancouver
Zhu Z, Yang Y, Pan L, Ma L, Fang L. Gut Microbiota Metabolic Reprogramming Drives Endocrine and Immune Resistance in Hormone-Dependent Cancers. Cancers. 2026;18(8):1218. doi:10.3390/cancers18081218
BibTeX
@article{Zhu2026,
author = {Zhu, Zhengqin and Yang, Yiting and Pan, Libin and Ma, Liefeng and Fang, Luo},
title = {Gut Microbiota Metabolic Reprogramming Drives Endocrine and Immune Resistance in Hormone-Dependent Cancers},
journal = {Cancers},
year = {2026},
volume = {18},
number = {8},
pages = {1218},
doi = {10.3390/cancers18081218}
}
EUVIMED